Metabolon Inks IP, Development Agreement with U. Michigan for Prostate Cancer Dx | GenomeWeb
NEW YORK (GenomeWeb News) – Metabolon said today that it has signed an intellectual property and development agreement with the University of Michigan related to its Prostarix line of prostate cancer diagnostics.
 
Under the terms of the agreement, Metabolon has taken an exclusive license for prostate cancer aggressiveness biomarkers that were discovered in a previous collaboration between the company and the university.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.